• 1. An AuNPs-functionalized AlGaN/GaN high electron mobility transistor sensor for ultrasensitive detection of TNT?
  Ying Li,Weirong Yao,Yunfei Xie,Renjun Pei RSC Adv., 2015,5, 98724-98729
• 2. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. Always a matter of interpretation: inferring student knowledge and understanding from research data
  Chem. Educ. Res. Pract., 2017,18, 7-12

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Recent Advances in the Study of 4-Methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxylic Acid (CAS: 1000342-75-5)

The compound 4-Methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid (CAS: 1000342-75-5) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This heterocyclic scaffold is particularly notable for its structural similarity to biologically active molecules, making it a promising candidate for the design of novel therapeutics. Recent studies have explored its synthesis, pharmacological properties, and potential mechanisms of action, shedding light on its versatility in targeting various disease pathways.

One of the key areas of research involving 4-Methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid is its role as a building block for kinase inhibitors. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is implicated in numerous diseases, including cancer and inflammatory disorders. Recent publications have demonstrated that derivatives of this compound exhibit potent inhibitory activity against specific kinases, such as JAK2 and EGFR, which are well-known targets in oncology. These findings highlight the compound's potential as a lead structure for the development of next-generation kinase inhibitors.

In addition to its kinase inhibitory properties, 4-Methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid has been investigated for its ability to modulate other biological targets. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported that this compound and its analogs interact with G-protein-coupled receptors (GPCRs), a large family of membrane proteins involved in various physiological processes. The study revealed that subtle modifications to the pyrrolopyridine core could significantly alter receptor binding affinity and selectivity, offering new avenues for drug design.

The synthetic accessibility of 4-Methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid has also been a focus of recent research. Advances in catalytic methods, such as transition metal-catalyzed C-H activation, have enabled more efficient and scalable routes to this scaffold. These developments are critical for facilitating structure-activity relationship (SAR) studies and accelerating the optimization of drug candidates. Furthermore, computational modeling and molecular docking studies have provided insights into the binding modes of this compound, aiding in the rational design of derivatives with improved pharmacological profiles.

Despite these promising advancements, challenges remain in the clinical translation of 4-Methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid-based therapeutics. Issues such as metabolic stability, bioavailability, and off-target effects need to be addressed through further preclinical studies. However, the growing body of research underscores the compound's potential as a versatile pharmacophore in medicinal chemistry. Future directions may include exploring its applications in combination therapies and expanding its use beyond oncology to other therapeutic areas, such as neurodegenerative and infectious diseases.

In conclusion, 4-Methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid (CAS: 1000342-75-5) represents a compelling case study in the intersection of chemical biology and drug discovery. Its unique structural features, combined with its diverse biological activities, make it a valuable tool for researchers aiming to develop innovative therapeutics. As the field continues to evolve, ongoing investigations into this compound are expected to yield further breakthroughs, solidifying its place in the pharmaceutical landscape.

• 889943-11-7(1H-Indole-3-carboxylicacid, 2,5-dimethyl-)
• 104175-33-9(2,6-Dimethylquinoline-4-carboxylic acid)
• 103986-06-7(2,3-Dimethyl-1H-indole-6-carboxylic Acid)
• 104785-55-9(2,4-Dimethylquinoline-3-carboxylic acid)
• 14844-73-6(2,3-Dimethyl-1H-indole-5-carboxylic acid)
• 634-37-7(2-methylquinoline-8-carboxylic acid)
• 63176-44-3(2-Methyl-1H-indole-3-carboxylic acid)
• 634-38-8(2-Methylquinoline-4-carboxylic acid)
• 88344-65-4(2-Methylquinoline-3,4-dicarboxylic acid)
• 634-39-9(2-methylquinoline-5-carboxylic acid)